Pundi AI partners with Waves AI: Transforming culture into verifiable intelligence
BlockBeats News, January 22, Pundi AI announced a partnership with the intelligent content oracle Waves AI to transform culture, sentiment, and narratives in Web3 into on-chain verifiable intelligent data. Waves AI captures community sentiment and cultural trends in real time, while Pundi AI provides the infrastructure to convert this data into trustworthy, verifiable, and community co-created on-chain assets, pioneering a new Web3 model of "culture as on-chain data."
Through this collaboration, cultural signals such as sentiment, trends, and narratives will be labeled as auditable on-chain datasets, available for use by AI agents, protocols, and applications, turning abstract emotions into learnable intelligent information. Pundi AI's "label-to-earn" model enables the community to participate in data labeling and receive rewards, while Waves AI gains access to high-quality training data. Together, they drive the integration of AI and culture, providing new possibilities for on-chain AI agents in trading, marketing, and governance, and helping to build an AI-native Web3 future.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
